

## OUTLINE

# Canadian Drug Benefit Plans Reference Guide – 2010 Edition

### EXECUTIVE SUMMARY

#### Table 1

Summary of Drug Plan Descriptions

- Region
- Legislative Authority
- Administration
- Plan Name
- Beneficiaries
- Generic Drug Substitution

#### Table 2

Provincial Professional Fees and Maximum Days Supply

- Province
- Professional Fees, Regular Prescription Maximum
- Mark-ups
- Maximum Days Supply/Prescription

#### Table 3

Provincial Co-Payments and Deductibles

- Province
- Deductible
- Co-Payment

#### Table 4

Listing Process Summary Table for Single-Source Drug Products

- Region
- Formulary Name
- Review by Independent Committee
- Formulary Publishing Dates
- Submission Deadlines

#### Table 5

Listing Process Summary Table for Interchangeable Products

- Region
- Formulary Name
- Review by Independent Committee
- Formulary Publishing Dates
- Submission Deadlines

#### Table 6

Time to Listing (from NOC) for Single Source Products Launched Between June 1, 2007 and May 31, 2009 (Full and Restricted Listings)

- Province
- No. of Listings
- Average TTL
- Range

#### Table 7

Population, Canada and the Provinces, 2002–2008

#### Table 8

Canada's Demographic Trends, 2000–2008

#### Table 9

National Drug Claims for Top 5 Selling Drugs in Canada, 2009

- Drug Product
- Total Claims
- Total Drug Cost Paid
- Average Drug Cost Paid
- Average Drug Cost per Claim
- Quantity Dispensed
- Average Drug Cost per Unit

### STATISTICAL TRENDS

#### Figure 1

Total Health Expenditure in Canada, by Use of Funds, 2008

#### Figure 2

Total Drug Expenditure in Canada and Prescribed Drugs by Payer, by Use of Funds, 2008

#### Figure 3

Total Health and Drug Expenditures in Canada 1998–2008

#### Figure 4

Total Health and Prescribed Drug Expenditures Per Capita, 1998–2008

#### Figure 5

Public Expenditures on Health and Prescribed Drugs, 1998–2008

#### Figure 6

Private Expenditures on Health and Prescribed Drugs, 1998–2008

#### Figure 7

Drug (& Personal Health Supplies) Expenditure by Province and by Type, 2008

#### Figure 8

Prescription Drug Expenditure in Canada, 1998–2008

#### Figure 9

Prescription Drug Expenditure by Province, 2008

#### Figure 10

Provincial Prescription Drug Expenditure per Capita, 2008

#### Figure 11

Prescription Drug Expenditure by Province and by Type, 2008

#### Figure 12

Manufacturers' Sales of Patented and Non-Patented Drugs 1998–2008

### COMMON DRUG REVIEW

#### 1.0 Introduction

#### 1.1 CDR History

#### 1.2 Common Drug Review

##### 1.2.1 Objectives

##### 1.2.2 Governance

##### 1.2.3 The CDR Within the Drug Review Process

##### 1.2.4 Manufacturers' Submission Process

##### 1.2.5 Pre-NOC Priority Review Submissions

##### 1.2.6 Post-NOC Priority Review

##### 1.2.7 Submission Requirements

###### 1.2.7.1 Category 1 Requirements

###### 1.2.7.2 Category 2 Requirements

###### 1.2.7.3 Additional Information

###### 1.2.7.4 Pre-NOC Priority Review Submission Requirements

###### 1.2.7.5 Format of Submissions

##### 1.2.8 Resubmissions Based on Reduced Price during the Embargo Period

##### 1.2.9 Resubmissions

###### 1.2.9.1 Resubmission Requirements

###### 1.2.9.2 Requirements for Resubmission Based on Reduced Price During Embargo Period

##### 1.2.10 Specialty Drugs

##### 1.2.11 Hospital Drugs

##### 1.2.12 Pilot Project: Subsequent Entry Biologics

##### 1.2.13 Pre-Submission Meetings

##### 1.2.14 Deadlines

#### 1.3 Transparency and Communications

#### 1.4 Completed Submissions – Time to Decision and Reasons for Recommendation

#### 1.5 CDR Directorate Current Staff Members

### APPENDIX I

Submission Items Required by the CDR

**APPENDIX II**

Participating F/P/T Drug Plans

**APPENDIX III**

Participating F/P/T Drug Plans and their Submission Requirements

**BRITISH COLUMBIA****1.0 Introduction****1.1 Drug Plan Expenditures and Use Profile**

1.1.1 Prescription Drug Plan Spending

1.1.2 Demographic profile

**1.2 Patient Eligibility for Drug Plan Coverage**

1.2.1 Seniors

1.2.2 Social Assistance

1.2.3 High-Cost to Income / Income-Based

1.2.4 Disease Specific

1.2.5 Others

**1.3 Pricing**

1.3.1 Low Cost Alternative Program

1.3.1.1 LCA Pricing Exceptions

1.3.1.2 Special Authorities for LCA Drugs

1.3.2 The Reference Drug Program

1.3.2.1 Reference Drug Program Special Authorities

1.3.3 Policy on Price Increases

**1.4 Drugs Eligible for Reimbursement**

1.4.1 Types of Benefit Status

1.4.2 Special Authorization Policy

1.4.2.1 Assumed Special Authorities

1.4.2.2 Super Categories

1.4.3 Reimbursement of Non-Listed Drug Products

1.4.4 Exclusions

**1.5 Submission and Drug Review Process**

1.5.1 Priority Review Policy

1.5.2 National Common Drug Review Submissions

1.5.3 Non-National Common Drug Review Submissions

1.5.3.1 Line Extensions, Resubmissions and New Indications

1.5.3.2 Interchangeable Drug Products

**1.6 Formulary****1.7 Advisory Committees****1.8 Organizational Chart****APPENDIX I**

Continuing Care Act

**ALBERTA****1.0 Introduction****1.1 Drug Plan Expenditures and Use Profile**

1.1.1 Prescription Drug Plan Spending

1.1.2 Demographic Profile

**1.2 Alberta Pharmaceutical Strategy****1.3 Patient Eligibility for Drug Plan Coverage**

1.3.1 Seniors

1.3.2 Social Assistance

1.3.3 Disease Specific

1.3.4 Other

**1.4 Pricing**

1.4.1 Least Cost Alternative (LCA) Pricing

1.4.2 Maximum Allowable Cost (MAC) Pricing

1.4.3 Policy on Price Increases

**1.5 Drugs Eligible for Reimbursement**

1.4.1 Criteria for Listing or Retaining Drug Products

1.4.2 Special Authorization Policy

1.4.3 Restricted Benefits

1.4.4 Limited Restricted Benefits

1.4.5 Reimbursement of Non-Listed Drug Products

1.4.6 Exclusions

**1.6 Submission and Drug Review Process**

1.6.1 Priority Review Policy

1.6.2 National Common Drug Review Submissions

1.6.3 Non-National Common Drug Review Submissions

1.5.3.1 New Chemical Entities/New Single Source Drug Products

1.5.3.2 Changes to Special Authorization or Restricted Benefit Status of Listed Single Source Drug Products Due to a New Indication

1.5.3.3 Line Extension Drug Products

1.5.3.4 Interchangeable Drug Products

1.5.3.5 Old Drug Products

1.5.3.6 Resubmissions

**1.7 Formulary****1.8 Advisory Committees**

1.8.1 Members

**1.8 Organizational Chart****SASKATCHEWAN****1.0 Introduction****1.1 Drug Plan Expenditures and Use Profile**

1.1.1 Prescription Drug Plan Spending

1.1.2 Demographic Profile

**1.2 Patient Eligibility for Drug Plan Coverage**

1.2.1 Seniors

1.2.2 Saskatchewan Assistance Plan (SAP)

1.2.3 Income-Based Program – Special Support Coverage

1.2.4 Disease Specific

1.2.5 Other

**1.3 Pricing**

1.3.1 Maximum Allowable Cost (MAC) Pricing

1.3.2 Interchangeability and Pricing

1.3.2.1 Low Cost Alternative

1.3.2.2 Standing Offer Contract (SOC)

1.3.3 Policy on Price Increases

**1.4 Drugs Eligible for Reimbursement**

1.4.1 Criteria for Listing or Retaining Drug Products

1.4.2 Exception Drug Status (EDS) Program

1.4.2.1 Exception Drug Status (EDS) Application Process

1.4.3 “No Substitution” Prescription Drug Coverage

1.4.4 Reimbursement of Non-Listed Drug Products

1.4.5 Exclusions

1.4.6 Policy for Formulary Deletion

**1.5 Submission and Drug Review Process**

1.5.1 Priority Review Policy

1.5.2 National Common Drug Review Submissions

1.5.3 Non-National Common Drug Review Submissions

1.5.3.1 Clinical Documentation

1.5.3.2 Manufacturing Documentation

1.5.3.3 Economic Evaluation

1.5.3.4 Additional Documentation Required

**1.6 Formulary****1.7 Advisory Committees**

1.7.1 Members

**1.8 Organizational Chart****APPENDIX I**

Product Submission Process Flowchart

**APPENDIX II**

The Prescription Drugs Act

**MANITOBA****1.0 Introduction****1.1 Drug Plan Expenditures and Use Profile**

1.1.1 Prescription Drug Plan Spending

1.1.2 Demographic Profile

**1.2 Patient Eligibility for Drug Plan Coverage**

1.2.1 Seniors

1.2.2 Social Assistance

1.2.3 High Cost to Income / Income-Based

1.2.4 Disease Specific

1.2.5 Other

**1.3 Pricing**1.3.1 *Policy on Price Increases***1.4 Drugs Eligible for Reimbursement**1.4.1 *Criteria for Listing or Retaining Drug Products*1.4.2 *Exception Drug Status Coverage*1.4.2.1 *Appeal Process for Exception Drug Status Coverage*1.4.3 *Policy for Formulary Deletion***1.5 Submission and Drug Review Process**1.5.1 *Priority Review Policy*1.5.2 *National Common Drug Review Submissions*1.5.3 *Non-National Common Drug Review Submissions*1.5.3.1 *Single Source Products That Do Not Contain New Chemical Entities*1.5.3.2 *Line Extensions*1.5.3.3 *Changes to Benefit Status of Listed Single Source Drug Products Due to a New Indication*1.5.3.4 *Interchangeable Drug Products*1.5.3.5 *Old Drug Products***1.6 Formulary****1.7 Advisory Committees**1.7.1 *Members***1.8 Organizational Chart****APPENDIX I**

Prescription Drugs Cost Assistance Act

**ONTARIO****1.0 Introduction****1.1 Drug Plan Expenditures and Use Profile**1.1.1 *Prescription Drug Plan Spending*1.1.2 *Demographic Profile***1.2 Patient Eligibility for Drug Plan Coverage**1.2.1 *Seniors*1.2.2 *Social Assistance*1.2.3 *High Cost to Income / Income-Based*1.2.4 *Disease Specific***1.3 Pricing**1.3.1 *Policy on Price Increases*1.3.2 *Cost to Operator Claims*1.3.3 *Interchangeable Drug Products***1.4 Drugs Eligible for Reimbursement**1.4.1 *Limited Use Products*1.4.2 *Conditional Listing*1.4.3 *Medically Necessary “No Substitution” Claims*1.4.4 *Reimbursement of Non-Listed Drug Products*1.4.4.1 *Exceptional Access Program*1.4.4.2 *Over-the-Counter Drug Products*1.4.5 *Interchangeable Products*1.4.5.1 *Off-Formulary Interchangeability*1.4.6 *Extemporaneous Preparations***1.5 Submission and Drug Review Process**1.5.1 *Priority Review Policy (Rapid Review Mechanism)*1.5.2 *National Common Drug Review Submissions*1.5.3 *Non-National Common Drug Review Submissions*1.5.3.1 *Line Extensions*1.5.3.2 *New Indications*1.5.3.3 *Interchangeable Drug Products*1.5.3.4 *Cancer Drugs***1.6 Formulary****1.7 Advisory Committees**1.7.1 *Members***1.8 Organizational Chart****APPENDIX I**

Ontario Regulations Made Under the ODBA

**APPENDIX II**

Ontario Regulations Made Under the DIDFA

**APPENDIX III**

Submission Consideration Process Flowchart

**QUEBEC****1.0 Introduction****1.1 Drug Plan Expenditures and Use Profile**1.1.1 *Prescription Drug Plan Spending*1.1.2 *Demographic Profile***1.2 Patient Eligibility for Drug Plan Coverage**1.2.1 *Seniors*1.2.2 *Social Assistance*1.2.3 *Other***1.3 Pricing**1.3.1 *Guaranteed Selling Price*1.3.2 *Establishing the Price Payable*1.3.2.1 *Actual Purchase Price*1.3.2.2 *The Lowest Price*1.3.2.3 *Accredited Drug Wholesaler's Mark-Up*1.3.2.4 *Maximum Amount*1.3.3 *Maximum Price Payable*1.3.4 *Policy on Price Increases***1.4 Drugs Eligible for Reimbursement**1.4.1 *Criteria for Listing or Retaining Drug Products*1.4.2 *Exception Drug Status*1.4.2.1 *Classification of Exception Drug Status Products*1.4.2.2 *Authorization for Payment and Duration of Authorization*1.4.2.3 *Codes of Exceptional Medications*1.4.3 *Reimbursement of Non-Listed Drug Products*1.4.3.1 *Objective*1.4.3.2 *Authorization for Payment by RAMQ (Health Insurance Board)*1.4.3.3 *Price Payable*1.4.4 *Smoking Cessation Products*1.4.5 *Extemporaneous Preparations*1.4.6 *Policy for Formulary Deletion***1.5 Submission and Drug Review Process**1.5.1 *Priority Review Policy*1.5.2 *Requirements for Manufacturers' Submissions*1.5.2.1 *First Application for a New Medication, for a New Indication of a Medication Already Listed or for a New Medication which is an Association of Medications*1.5.2.2 *For a New Pharmaceutical Form of a Medication Already Listed*1.5.2.3 *For a New Strength of a Medication Already Listed*1.5.2.4 *Re-Evaluation Application for a New Medication of for a New Indication of a Medication Already Listed*1.5.2.5 *First Application for a Generic Medication*1.5.2.6 *Re-Evaluation Application for a Generic Medication*1.5.3 *Request for Review of Decision***1.6 Formulary****1.7 Advisory Committees**1.7.1 *Committee Members***1.8 Organizational Chart****APPENDIX I**

Loi sur l'Assurance Médicaments

**NEW BRUNSWICK****1.0 Introduction****1.1 Drug Plan Expenditures and Use Profile**1.1.1 *Prescription Drug Plan Spending*1.1.2 *Demographic Profile***1.2 Patient Eligibility for Drug Plan Coverage**1.2.1 *Seniors*1.2.2 *Social Assistance*1.2.3 *Disease Specific*1.2.4 *Others***1.3 Pricing**1.3.1 *Policy on Price Increases***1.4 Drugs Eligible for Reimbursement**

- 1.4.1 *Special Authorization Process*
- 1.4.2 *Reimbursement of Non-Listed Drug Products*
- 1.4.3 *Exclusions*
- 1.4.4 *Extemporaneous Preparations*
- 1.5 Submission and Drug Review Process**
- 1.5.1 *Priority Review Policy*
- 1.5.2 *National Common Drug Review Submissions*
- 1.5.3 *Non-National Common Drug Review Submissions*
  - 1.5.3.1 *Process for Submission*
  - 1.5.3.2 *Line Extension Submission Requirements*
  - 1.5.3.3 *New Indication Submission Requirements*
  - 1.5.3.4 *Resubmission Requirements*
  - 1.5.3.5 *Interchangeable Drug Products*
- 1.6 Formulary**
- 1.7 Advisory Committees**
- 1.7.1 *Members*
- 1.8 Organizational Chart**

**APPENDIX I**

Drug Review Process for the Atlantic Provinces

**NOVA SCOTIA**

- 1.0 Introduction**
- 1.1 Drug Plan Expenditures and Use Profile**
- 1.1.1 *Provincial Drug Plan Spending*
- 1.1.2 *Demographic Profile*
- 1.2 Patient Eligibility for Drug Plan Coverage**
- 1.2.1 *Seniors*
- 1.2.2 *Social Assistance*
- 1.2.3 *Disease Specific*
- 1.2.4 *Other*
- 1.3 Pricing**
- 1.3.1 *Actual Acquisition Costs (AAC)*
- 1.3.2 *Maximum Allowable Cost (MAC)*
  - 1.3.2.1 *Pharmacare Allowance*
  - 1.3.2.2 *Special MAC Categories*
- 1.3.3 *Policy on Price Increases*
- 1.4 Drugs Eligible for Reimbursement**
- 1.4.1 *Exception Status Drugs*
  - 1.4.1.1 *Notification*
  - 1.4.1.2 *Billing*
- 1.4.2 *Reimbursement of Non-Listed Drug Products*
- 1.4.3 *Benefit Exclusions*
- 1.4.4 *Policy for Product Deletions*
- 1.5 Submission and Drug Review Process**
- 1.5.1 *Priority Review Policy*
- 1.5.2 *National Common Drug Review Submissions*
- 1.5.3 *Non-National Common Drug Review Submissions*
  - 1.5.3.1 *Process for Submission*
  - 1.5.3.2 *Line Extension Submission Requirements*
  - 1.5.3.3 *New Indication Submission Requirements*
  - 1.5.3.4 *Resubmission Requirements*
  - 1.5.3.5 *Interchangeable Drugs*
- 1.6 Formulary**
- 1.7 Advisory Committees**
- 1.7.1 *Members*
- 1.8 Organizational Chart**

**APPENDIX I**

Drug Review Process for the Atlantic Provinces

**PRINCE EDWARD ISLAND**

- 1.0 Introduction**
- 1.1 Drug Plan Expenditures and Use Profile**
- 1.1.1 *Prescription Drug Plan Spending*
- 1.1.2 *Demographic Profile*
- 1.2 Patient Eligibility for Drug Plan Coverage**
- 1.2.1 *Seniors*
- 1.2.2 *Social Assistance*

- 1.2.3 *High Cost to Income*
- 1.2.4 *Disease Specific*
- 1.2.5 *Other*
- 1.3 Pricing**
- 1.3.1 *Policy on Price Increases*
- 1.4 Drugs Eligible for Reimbursement**
- 1.4.1 *Exception Drug Status*
- 1.4.2 *"No Substitution" Prescriptions*
- 1.4.3 *Reimbursement of Non-Listed Drug Products*
- 1.4.4 *Interchangeable Products*
- 1.4.5 *Exclusions*
- 1.4.6 *Extemporaneous Preparations*
- 1.4.7 *Policy for Product Deletions*
- 1.5 Submission and Drug Review Process**
- 1.5.1 *Priority Review Policy*
- 1.5.2 *National Common Drug Review Submissions*
- 1.5.3 *Non-National Common Drug Review Submissions*
  - 1.5.3.1 *Process for Submission*
  - 1.5.3.2 *Line Extension Submission Requirements*
  - 1.5.3.3 *New Indication Submission Requirements*
  - 1.5.3.4 *Resubmission Requirements*
  - 1.5.3.5 *Interchangeable Drug Products*

**1.6 Formulary****1.7 Advisory Committees**

- 1.7.1 *Members*

**1.8 Organizational Chart****APPENDIX I**

Drug Cost Assistance Act

**APPENDIX II**

Drug Review Process for the Atlantic Provinces

**NEWFOUNDLAND**

- 1.0 Introduction**
- 1.1 Drug Plan Expenditures and Use Profile**
- 1.1.1 *Prescription Drug Plan Spending*
- 1.1.2 *Demographic Profile*
- 1.2 Patient Eligibility for Drug Plan Coverage**
- 1.2.1 *Seniors*
- 1.2.2 *Social Assistance*
- 1.2.3 *High Cost to Income / Income-Based*
- 1.2.4 *Disease Specific*
- 1.3 Pricing**
- 1.3.1 *Reasonable Based Pricing*
- 1.3.2 *Policy on Price Increases*
- 1.3.3 *Interchangeable Drug Products*
  - 1.3.3.1 *Maximum Prices*
  - 1.3.3.2 *Mandatory Substitution/Charge of Lowest Price*
- 1.4 Drugs Eligible for Reimbursement**
- 1.4.1 *Therapeutic Class Reviews*
- 1.4.2 *Special Authorization Process*
- 1.4.3 *Reimbursement of Non-Listed Drug Products*
- 1.4.4 *Exclusions*
- 1.5 Submission and Drug Review Process**
- 1.5.1 *Priority Review Policy*
- 1.5.2 *National Common Drug Review Submissions*
- 1.5.3 *Non-National Common Drug Review Submissions*
  - 1.5.3.1 *Process for Submission*
  - 1.5.3.2 *Line Extension Submission Requirements*
  - 1.5.3.3 *New Indication Submission Requirements*
  - 1.5.3.4 *Resubmission Requirements*
  - 1.5.3.5 *Interchangeable Drug Products*

**1.6 Formulary****1.7 Advisory Committees**

- 1.7.1 *Members*

**1.8 Organizational Chart****APPENDIX I**

Drug Review Process for the Atlantic Provinces

**VETERANS AFFAIRS CANADA**

- 1.0 Introduction**
- 1.1 Drug Expenditures and Use Profile**
  - 1.1.1 Prescription Drug Plan Spending
  - 1.1.2 Demographic Profile
- 1.2 Patient Eligibility for Drug Plan Coverage**
- 1.3 Pricing**
  - 1.3.1 Special Authorization Process
  - 1.3.2 Exclusions
- 1.4 Submission and Drug Review Process**
  - 1.4.1 National Common Drug Review Submissions
  - 1.4.2 Non-National Common Drug Review Submissions
    - 1.4.2.1 Line Extensions, New Indications and New Dosage Forms
    - 1.4.2.2 Interchangeable Drug Products
- 1.5 Formulary**
- 1.6 Advisory Committees**
  - 1.6.1 Members

**NON-INSURED HEALTH BENEFITS**

- 1.0 Introduction**
- 1.1 Drug Expenditures and Use Profile**
  - 1.1.1 Prescription Drug Plan Spending
  - 1.1.2 Demographic Profile
- 1.2 Patient Eligibility for Drug Plan Coverage**
- 1.3 Pricing**
  - 1.3.1 Policy on Price Increases
- 1.4 Drugs Eligible for Reimbursement**
  - 1.4.1 Criteria for Listing or Retaining Drug Products
  - 1.4.2 Limited Use Benefits
  - 1.4.3 Prior Approval Process
  - 1.4.4 Medically Necessary “No Substitution” Claims
  - 1.4.5 Reimbursement of Non-Listed Drug Products / Exception Criteria
  - 1.4.6 Exclusions
  - 1.4.7 Extemporaneous Mixtures
  - 1.4.8 Policy for Formulary Deletion
- 1.5 Submission and Drug Review Process**
  - 1.5.1 Priority Review Policy
  - 1.5.2 National Common Drug Review Submissions
  - 1.5.3 Non-National Common Drug Review Submissions
    - 1.5.3.1 Drug Products Other Than New Chemical Entities / New Combination / Interchangeable Products
    - 1.5.3.2 Interchangeable Drug Products
- 1.6 Formulary**
  - 1.6.1 Special Formulary for Chronic Renal Failure Patients
- 1.7 Advisory Committees**
  - 1.7.1 Members
- 1.8 Organizational Chart**

**DEPARTMENT OF NATIONAL DEFENCE**

- 1.0 Introduction**
- 1.1 Drug Plan Demographic Profile**
- 1.1 Patient Eligibility for Drug Plan Coverage**
- 1.2 Pricing**
- 1.4 Drugs Eligible for Reimbursement**
  - 1.4.1 Types of Drug Benefit Listing
  - 1.4.2 Special Authorization Process
    - 1.4.2.1 The Role of the CF Drug Exception Centre
  - 1.4.3 Over-the-Counter Drugs (OTC) and Personal Health Supplies
  - 1.4.4 Exclusions
- 1.5 Submission and Drug Review Process**
  - 1.5.1 National Common Drug Review Submissions
  - 1.5.2 Non-National Common Drug Review Submissions
    - 1.5.2.1 Interchangeable Drug Products

- 1.6 Formulary**
- 1.7 Advisory Committees**
  - 1.7.1 Members

**CORRECTIONAL SERVICE CANADA**

- 1.0 Introduction**
- 1.1 Drug Plan Expenditures and Use Profile**
  - 1.1.1 Prescription Drug Plan Spending
  - 1.1.2 Demographic Profile
- 1.2 Plan Description**
  - 1.2.1 Patient Eligibility
  - 1.2.2 Organization of CSC Health Services
  - 1.2.3 CSC Drug Supply Process
  - 1.2.4 Medication Distribution
  - 1.2.5 Special Drugs Programs
- 1.3 Drugs Eligible for Reimbursement**
  - 1.3.1 Criteria for Listing or Retaining Drug Products – Ontario Region
    - 1.3.2 Special Authorization Process
    - 1.3.3 Restrictions
    - 1.3.4 Therapeutic Interchange Policy – Ontario Region
- 1.4 Submission and Drug Review Process**
  - 1.4.1 National Common Drug Review Submissions
  - 1.4.2 Non-National Common Drug Review Submissions
    - 1.4.2.1 Interchangeable Drug Products
- 1.5 Formulary**
  - 1.5.1 The Ontario Regional Drug Formulary
- 1.6 Advisory Committees**
  - 1.6.1 Members

**CANCER PROGRAMS**

- 1.9 Introduction**
- 1.10 Joint Oncology Drug Review**
- 1.11 British Columbia**
  - 1.11.1 British Columbia Cancer Agency
- 1.12 Alberta**
  - 1.12.1 Alberta Health and Alberta Cancer Board Outpatient Cancer Drug Benefit Program
- 1.13 Saskatchewan**
  - 1.3.1 Saskatchewan Cancer Agency
- 1.14 Manitoba**
  - 1.4.1 Manitoba PharmaCare and CancerCare Manitoba
- 1.15 Ontario**
  - 1.5.1 Submission Process for Cancer-Related Drugs
  - 1.5.2 New Drug Funding Program, Cancer Care Ontario
  - 1.5.3 Free Drug Services, Cancer Care Ontario
- 1.16 Quebec**
- 1.17 New Brunswick**
- 1.18 Nova Scotia**
  - 1.8.1 Drug Assistance for Cancer Patients Program
- 1.19 Prince Edward Island**
  - 1.9.1 High Cost Drugs Program (M)
- 1.20 Newfoundland and Labrador**
  - 1.1.10 Cancer and HIV/AIDS Drugs

**BLOOD AGENCIES**

- 1.0 Introduction**
- 1.1 Blood Management in Canada**

- 1.1.1 *Canadian Blood Services*
  - 1.1.1.1 *Mission*
  - 1.1.1.2 *Values*
  - 1.1.1.3 *Participating Ministers of Health*
  - 1.1.1.4 *Transfusion Committee*
  - 1.1.1.5 *Governance Structure*
  - 1.1.1.6 *Members*
- 1.1.2 *Hema-Quebec*
  - 1.1.2.1 *SIATH*
- 1.2 Submission and Drug Review Process**
  - 1.2.1 *Canadian Blood Services*
  - 1.2.2 *Quebec*
- 1.3 Advisory Committees**
  - 1.3.1 *Canadian Blood Services*
  - 1.3.2 *Quebec*

## PUBLIC HEALTH VACCINES

- 1.0 Introduction**
- 1.1 Types of Vaccines**
- 1.2 Reimbursement of Vaccines in Canada**
  - 1.2.1 *Public Health Network*
  - 1.2.2 *National Advisory Committee on Immunization*
    - 1.2.2.1 *Role and Responsibilities*
    - 1.2.2.2 *Governance Structure*
    - 1.2.2.3 *Meetings*
    - 1.2.2.4 *Publications*
  - 1.2.3 *Canadian Immunization Committee*
  - 1.2.4 *Communicable Disease Control Expert Group*
  - 1.2.5 *Provincial and Territorial Responsibilities*
- 1.3 Submission and Drug Review Process**
  - 1.3.1 *Basis of NACI Recommendations*
    - 1.3.1.1 *Publication of Recommendations*

## CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH (CADTH)

- 1.0 Introduction**
- 1.1 Products and Publications**
- 1.2 Research Programs**
  - 1.2.1 *Health Technology Assessments*
  - 1.2.2 *Steps of the HTA Process*
  - 1.2.3 *Current Pharmaceutical Projects by CADTH*
  - 1.2.4 *Upcoming Pharmaceutical Projects by CADTH*
- 1.3 Board of Directors**
- 1.4 Advisory Committees**
  - 1.4.1 *Devices and Systems Advisory Committee (DSAC)*
  - 1.4.2 *Advisory Committee on Pharmaceuticals (ACP)*
  - 1.4.3 *Canadian Expert Advisory Committee (CEDAC)*
  - 1.4.4 *Governance*
- 1.5 Canadian Optimal Medication Prescribing & Utilization Service (COMPUS)**
  - 1.5.1 *Purpose*
  - 1.5.2 *Activities*
  - 1.5.3 *Priority Areas*
  - 1.5.4 *COMPUS Advisory Committee Members*
  - 1.5.5 *COMPUS Expert Review Panel*
  - 1.5.6 *COMPUS Expert Review Committee*

## PATENTED MEDICINE PRICES REVIEW BOARD (PMPRB)

- 1.0 Overview**
- 1.1 Introduction**
- 1.2 Origin of the PMPRB**
- 1.3 Mandate of the PMPRB**
- 1.4 Jurisdiction**
- 1.5 Governance**

- 1.6 Budget**
- 1.7 Regulatory Reporting Requirements**
- 1.8 Price Regulation Factors**
- 1.9 Excessive Price Guidelines**
- 1.10 Remedies**
- 2.0 Policies**
  - 2.1 *Patent Pending Policy*
  - 2.2 *Patent Dedication Policy*
  - 2.3 *Policy on the Meaning of Medicine*
  - 2.4 *Policy on Unit of Price Review*
  - 2.5 *Policy for when a Price May be Considered Excessive*
  - 2.6 *Policy on the Use of Patented and Non-Patented Drug Products in Price Tests*
  - 2.7 *Policy on the Offset of Excessive Revenues*

- 3.0 Guidelines and Procedures**
  - 3.1 The Scientific Price Review**
    - 3.1.1 *Sources of Scientific Information*
    - 3.1.2 *Human Drug Advisory Panel*
    - 3.1.3 *Determining the Primary Indication/Use of a New Patented Medicine*
    - 3.1.4 *The Level of Therapeutic Improvement*
    - 3.1.5 *Factors Considered in Recommending the Level of Therapeutic Improvement*
    - 3.1.6 *Methodology for the Evaluation of the Level of Therapeutic Improvement*
    - 3.1.7 *Selection of Drug Products to be Used for Comparison Purposes and Comparable Dosage Regimens*
  - 3.2 The Price Review Process**
    - 3.2.1 *Introductory Price Review*
    - 3.2.2 *Review of Prices of Existing Patented Drug Products*
  - 3.3 Investigations**
    - 3.3.1 *Where the Price Appears Non-Excessive*
    - 3.3.2 *Voluntary Compliance Undertaking*

- 4.0 Schedules**
  - 4.1 **Schedule 1 – Submissions by Patentees on Level of Therapeutic Improvement**
  - 4.2 **Schedule 2 – Comparable Dosage Forms**
  - 4.3 **Schedule 3 – Therapeutic Class Comparison Test**
  - 4.4 **Schedule 4 – Reasonable Relationship Test**
  - 4.5 **Schedule 5 – Median International Price Comparison Test**
  - 4.6 **Schedule 6 – Highest International Price Comparison Test**
  - 4.7 **Schedule 7 – International Therapeutic Class Comparison Test**
  - 4.8 **Schedule 8 – Application of Price Tests for New Drug Products**
  - 4.9 **Schedule 9 – CPI-Adjustment Methodology**
  - 4.10 **Schedule 10 – DIP Methodology**
  - 4.11 **Schedule 11 – Criteria for Commencing an Investigation**
  - 4.12 **Schedule 12 – “Any Market” Price Reviews**
  - 4.13 **Schedule 13 – Offset of Excess Revenues**

- 5.0 Members of the PMPRB and Senior Staff and HDAP**

- 6.0 Contact Information**

## NATIONAL PRESCRIPTION DRUG UTILIZATION INFORMATION SYSTEM (NPDUIS)

- 1.0 Background**
  - 1.1 *Role*
  - 1.2 *Database*
  - 1.3 *NPDUIS Initiatives*

- 1.3.1 *Projects*
- 1.3.2 *Publications and Products*
- 1.3.3 *Analytical Study Series*
- 1.4 **NPDUIS Database Advisory Group**

## **PRIVATE PAYERS**

- 1.0 **Introduction**
- 1.1 **Drug Plan Expenditures and Use Profile**
  - 1.1.1 *Prescription Drug Plan Spending*
  - 1.1.2 *Demographic Profile*
- 1.2 **Plan Description**
  - 1.2.1 *Plan Members Weigh In*
- 1.3 **Reimbursement**
- 1.4 **Pharmacy Benefit Managers**
  - 1.4.1 *Telus Health Solutions - Emergis*
  - 1.4.2 *ESI Canada*
  - 1.4.3 *Claimsecure*
  - 1.4.4 *Blue Cross*
  - 1.4.5 *Green Shield Canada*
  - 1.4.6 *NexGenRx*
  - 1.4.7 *Manulife Financial*
  - 1.4.8 *Lawton's Managed Health Care Services*
- 1.5 **Approval/Listing Process**
- 1.6 **Requirements for Manufacturers' Submissions**
  - 1.6.1 *Submissions to Emergis National Formulary*
  - 1.6.2 *Private Payers Submissions Contacts*
- 1.7 **Formularies**

## **GLOSSARY**